Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Februar 2024 16:05 ET | Quelle: IO Biotech

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech to Present at 44th Annual Cowen Health Care Conference
21. Dezember 2023 08:30 ET | Quelle: IO Biotech

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
13. November 2023 08:12 ET | Quelle: IO Biotech

IO Biotech Announces 2023 Third Quarter Results

IO Biotech Announces 2023 Third Quarter Results
13. November 2023 08:00 ET | Quelle: IO Biotech

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

IO Biotech Appoints Helen Collins, MD, to its Board of Directors
10. November 2023 08:00 ET | Quelle: IO Biotech

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
08. November 2023 16:30 ET | Quelle: IO Biotech

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences
01. November 2023 08:30 ET | Quelle: IO Biotech

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
23. Oktober 2023 01:00 ET | Quelle: IO Biotech

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced...
03. Oktober 2023 16:30 ET | Quelle: IO Biotech

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
12. September 2023 08:05 ET | Quelle: IO Biotech

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO...

Vorherige Seite

Nächste Seite